# US 2025/0026816 A1 · Antibodies for Use as Therapeutics Against Bacterial Infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0026816 A1
- Document ID: US20250026816A1
- Status: Published application
- Kind: A1
- Application number: 18/713,540
- Filed: 2022-11-25
- Published: 2025-01-23
- Earliest claimed: 2021-11-26
- Assignees: Kymab Limited
- Applicants: Kymab Limited
- Inventors: Stephen REECE; Aisha KRISHNA; Siobhan O'LEARY; Josefin BARTHOLDSON SCOTT; Simon WATSON; Stephen BAKER
- Web page: https://patentgrep.com/patent/US20250026816A1

## CPC

- C07K 16/1203: Gram-negative bacteria
- C07K 16/1218: Acinetobacter (G)
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61P 31/04: Antibacterial agents
- C07K 16/40: against enzymes
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to antibodies that bind Acinetobacter baumannii, and their use in the diagnosis of, and the prevention and treatment of, bacterial infection caused by Acinetobacter baumannii. In particular, the present invention relates to monoclonal antibodies that specifically bind at the bacterial wall of Acinetobacter baumannii bacteria, such as on, e.g., living bacteria.

## Claims

### Claim 1

An antibody that specifically binds at the surface of Acinetobacter baumannii bacteria.

### Claim 2 (depends on 1)

An antibody according to claim 1, wherein the antibody induces complement activation (e.g. as measured by flow cytometry-based assay).

### Claim 3 (depends on 1, 2)

An antibody according to claim 1 or claim 2, that specifically binds to Oxa-23 at the surface of Acinetobacter baumannii bacteria.

### Claim 4 (depends on 1, 2)

An antibody according to claim 1 or claim 2, that specifically binds Oxa-23 on outer membrane vesicles (OMVs) of Acinetobacter baumannii bacteria.

### Claim 5 (depends on 1, 2, 3, 4)

An antibody according to any one of claims 1 to 4, wherein the antibody comprises a variable heavy (VH) domain sequence comprising complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, and a variable light (VL) domain sequence comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, and wherein the HCDR3 is selected from the group consisting of SEQ ID NO: 34, SEQ ID NO: 24, SEQ ID NO: 174, and SEQ ID NO: 182.

### Claim 6 (depends on 1, 2, 3, 4)

An antibody according to any one of the claims 1 to 4, wherein the antibody comprises a variable heavy (VH) domain sequence comprising complementarity determining regions (CDRs) HCDR1, HCDR2, and HCDR3, and a variable light (VL) domain sequence comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, and wherein:
(i) HCDR1 consists of SEQ ID NO: 32, HCDR2 consists of SEQ ID NO: 33, HCDR3 consists of SEQ ID NO: 34, LCDR1 consists of SEQ ID NO: 37, LCDR2 consists of SEQ ID NO: 28, and LCDR3 consists of SEQ ID NO: 38,
(ii) HCDR1 consists of SEQ ID NO: 22, HCDR2 consists of SEQ ID NO: 23, HCDR3 consists of SEQ ID NO: 24, LCDR1 consists of SEQ ID NO: 27, LCDR2 consists of SEQ ID NO: 28, and LCDR3 consists of SEQ ID NO: 29,
(iii) HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 173, HCDR3 consists of SEQ ID NO: 174, LCDR1 consists of SEQ ID NO: 149, LCDR2 consists of SEQ ID NO: 177, and LCDR3 consists of SEQ ID NO: 178, or
(iv) HCDR1 consists of SEQ ID NO: 181, HCDR2 consists of SEQ ID NO: 173, HCDR3 consists of SEQ ID NO: 182, LCDR1 consists of SEQ ID NO: 185, LCDR2 consists of SEQ ID NO: 28, and LCDR3 consists of SEQ ID NO: 186.

### Claim 7 (depends on 1, 2, 3, 4)

An antibody according to any one of claims 1 to 4, wherein the antibody comprises a variable heavy (VH) domain sequence and a variable light (VL) domain sequence and wherein:
(i) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 31 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO:36,
(ii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 21 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 26,
(iii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 172 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO:176, or
(iv) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 180 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO:184,
optionally with 1, 2, 3, 4 or 5 amino acid alterations outside the complementarity determining regions (CDRs) in the variable heavy (VH) domain sequence and optionally with 1, 2, 3, 4 or 5 amino acid alterations outside the complementarity determining regions (CDRs) in the variable light (VL) domain sequence.

### Claim 8 (depends on 1, 2, 3, 4)

An antibody according to any one of claims 1 to 4, wherein the antibody comprises a variable heavy (VH) domain sequence and a variable light (VL) domain sequence and wherein:
(i) the variable heavy (VH) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 31 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 36,
provided that HCDR1 consists of SEQ ID NO: 32, HCDR2 consists of SEQ ID NO: 33, HCDR3 consists of SEQ ID NO: 34, LCDR1 consists of SEQ ID NO: 37, LCDR2 consists of SEQ ID NO: 28, and LCDR3 consists of SEQ ID NO: 38,
(ii) the variable heavy (VH) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 21 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 26,
provided that HCDR1 consists of SEQ ID NO: 22, HCDR2 consists of SEQ ID NO: 23, HCDR3 consists of SEQ ID NO: 24, LCDR1 consists of SEQ ID NO: 27, LCDR2 consists of SEQ ID NO: 28, and LCDR3 consists of SEQ ID NO: 29,
(iii) the variable heavy (VH) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 172 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 176,
provided that HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 173, HCDR3 consists of SEQ ID NO: 174, LCDR1 consists of SEQ ID NO: 149, LCDR2 consists of SEQ ID NO: 177, and LCDR3 consists of SEQ ID NO: 178, or
(iv) the variable heavy (VH) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 180 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 184,
provided that HCDR1 consists of SEQ ID NO: 181, HCDR2 consists of SEQ ID NO: 173, HCDR3 consists of SEQ ID NO: 182, LCDR1 consists of SEQ ID NO: 185, LCDR2 consists of SEQ ID NO: 28, and LCDR3 consists of SEQ ID NO: 186.

### Claim 9 (depends on 1, 2, 3, 4)

An antibody according to any one of claims 1 to 4, wherein the antibody comprises a variable heavy (VH) domain sequence and a variable light (VL) domain sequence and wherein:
(i) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 31 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO:36,
(ii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 21 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 26,
(iii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 172 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO:176, or
(iv) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 180 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO:184.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

An antibody that binds to the same epitope on Oxa-23 as an antibody according to any one of claims 1 to 9.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

An antibody capable of competing for binding to Oxa-23 with an antibody according to any one of claims 1 to 9.

### Claim 12 (depends on 1, 2)

An antibody according to claim 1 or claim 2, that specifically binds OCL1 lipooligosaccharide (LOS) at the surface of Acinetobacter baumannii bacteria.

### Claim 13 (depends on 1, 2)

An antibody according to claim 1 or claim 2, that specifically binds OCL1 LOS on outer membrane vesicles (OMVs) of Acinetobacter baumannii bacteria.

### Claim 14 (depends on 12, 13)

An antibody according to claim 12 or claim 13, wherein the antibody comprises a variable heavy (VH) domain sequence comprising complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, and a variable light (VL) domain sequence comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, and wherein the HCDR3 is selected from the group consisting of SEQ ID NO: 189, SEQ ID NO: 196, SEQ ID NO: 90, SEQ ID NO: 105, SEQ ID NO: 112, SEQ ID NO:
119, and SEQ ID NO: 146.

### Claim 15 (depends on 12, 13)

An antibody according to claim 12 or claim 13, wherein the antibody comprises a variable heavy (VH) domain sequence comprising complementarity determining regions (CDRs) HCDR1, HCDR2, and HCDR3, and a variable light (VL) domain sequence comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, and wherein:
(i) HCDR1 consists of SEQ ID NO: 32, HCDR2 consists of SEQ ID NO: 33, HCDR3 consists of SEQ ID NO: 189, LCDR1 consists of SEQ ID NO: 37, LCDR2 consists of SEQ ID NO: 28, and LCDR3 consists of SEQ ID NO: 192,
(ii) HCDR1 consists of SEQ ID NO: 195, HCDR2 consists of SEQ ID NO: 33, HCDR3 consists of SEQ ID NO: 196, LCDR1 consists of SEQ ID NO: 37, LCDR2 consists of SEQ ID NO: 9, and LCDR3 consists of SEQ ID NO: 199,
(iii) HCDR1 consists of SEQ ID NO: 22, HCDR2 consists of SEQ ID NO: 89, HCDR3 consists of SEQ ID NO: 90, LCDR1 consists of SEQ ID NO: 93, LCDR2 consists of SEQ ID NO: 28, and LCDR3 consists of SEQ ID NO: 94,
(iv) HCDR1 consists of SEQ ID NO: 104, HCDR2 consists of SEQ ID NO: 33, HCDR3 consists of SEQ ID NO: 105, LCDR1 consists of SEQ ID NO: 27, LCDR2 consists of SEQ ID NO: 28, and LCDR3 consists of SEQ ID NO: 108,
(v) HCDR1 consists of SEQ ID NO: 111, HCDR2 consists of SEQ ID NO: 33, HCDR3 consists of SEQ ID NO: 112, LCDR1 consists of SEQ ID NO: 115, LCDR2 consists of SEQ ID NO: 28, and LCDR3 consists of SEQ ID NO: 116,
(vi) HCDR1 consists of SEQ ID NO: 104, HCDR2 consists of SEQ ID NO: 33, HCDR3 consists of SEQ ID NO: 119, LCDR1 consists of SEQ ID NO: 122, LCDR2 consists of SEQ ID NO: 28, and LCDR3 consists of SEQ ID NO: 123, or
(vii) HCDR1 consists of SEQ ID NO: 145, HCDR2 consists of SEQ ID NO: 33, HCDR3 consists of SEQ ID NO: 146, LCDR1 consists of SEQ ID NO: 149, LCDR2 consists of SEQ ID NO: 150, and LCDR3 consists of SEQ ID NO: 151.

### Claim 16 (depends on 12, 13)

An antibody according to claim 12 or claim 13, wherein the antibody comprises a variable heavy (VH) domain sequence and a variable light (VL) domain sequence and wherein:
(i) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 188 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 191,
(ii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 194 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 198,
(iii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 88 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 92,
(iv) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 103 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 107,
(v) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 110 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 114,
(vi) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 118 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 121, or
(vii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 144 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 148,
optionally with 1, 2, 3, 4 or 5 amino acid alterations outside the complementarity determining regions (CDRs) in the variable heavy (VH) domain sequence and optionally with 1, 2, 3, 4 or 5 amino acid alterations outside the complementarity determining regions (CDRs) in the variable light (VL) domain sequence.

### Claim 17 (depends on 12, 13)

An antibody according to claim 12 or claim 13, wherein the antibody comprises a variable heavy (VH) domain sequence and a variable light (VL) domain sequence and wherein:
(i) the variable heavy (VH) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 188 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 191,
provided that HCDR1 consists of SEQ ID NO: 32, HCDR2 consists of SEQ ID NO: 33, HCDR3 consists of SEQ ID NO: 189, LCDR1 consists of SEQ ID NO: 37, LCDR2 consists of SEQ ID NO: 28, and LCDR3 consists of SEQ ID NO: 192,
(ii) the variable heavy (VH) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 194 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 198,
provided that HCDR1 consists of SEQ ID NO: 195, HCDR2 consists of SEQ ID NO: 33, HCDR3 consists of SEQ ID NO: 1%, LCDR1 consists of SEQ ID NO: 37, LCDR2 consists of SEQ ID NO: 9, and LCDR3 consists of SEQ ID NO: 199,
(iii) the variable heavy (VH) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 88 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 92,
provided that HCDR1 consists of SEQ ID NO: 22, HCDR2 consists of SEQ ID NO: 89, HCDR3 consists of SEQ ID NO: 90, LCDR1 consists of SEQ ID NO: 93, LCDR2 consists of SEQ ID NO: 28, and LCDR3 consists of SEQ ID NO: 94,
(iv) the variable heavy (VH) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 103 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 107,
provided that HCDR1 consists of SEQ ID NO: 104, HCDR2 consists of SEQ ID NO: 33, HCDR3 consists of SEQ ID NO: 105, LCDR1 consists of SEQ ID NO: 27, LCDR2 consists of SEQ ID NO: 28, and LCDR3 consists of SEQ ID NO: 108,
(v) the variable heavy (VH) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 110 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 114,
provided that HCDR1 consists of SEQ ID NO: 111, HCDR2 consists of SEQ ID NO: 33, HCDR3 consists of SEQ ID NO: 112, LCDR1 consists of SEQ ID NO: 115, LCDR2 consists of SEQ ID NO: 28, and LCDR3 consists of SEQ ID NO: 116,
(vi) the variable heavy (VH) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 118 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 121,
provided that HCDR1 consists of SEQ ID NO: 104, HCDR2 consists of SEQ ID NO: 33, HCDR3 consists of SEQ ID NO: 119, LCDR1 consists of SEQ ID NO: 122, LCDR2 consists of SEQ ID NO: 28, and LCDR3 consists of SEQ ID NO: 123, or
(vii) the variable heavy (VH) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 144 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99%/identity to SEQ ID NO: 148,
provided that HCDR1 consists of SEQ ID NO: 145, HCDR2 consists of SEQ ID NO: 33, HCDR3 consists of SEQ ID NO: 146, LCDR1 consists of SEQ ID NO: 149, LCDR2 consists of SEQ ID NO: 150, and LCDR3 consists of SEQ ID NO: 151.

### Claim 18 (depends on 12, 13)

An antibody according to claim 12 or claim 13, wherein the antibody comprises a variable heavy (VH) domain sequence and a variable light (VL) domain sequence and wherein:
(i) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 188 and the variable light (VL) domain comprises SEQ ID NO: 191,
(ii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 194 and the variable light (VL) domain comprises SEQ ID NO: 198,
(iii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 88 and the variable light (VL) domain comprises SEQ ID NO: 92,
(iv) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 103 and the variable light (VL) domain comprises SEQ ID NO: 107,
(v) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 110 and the variable light (VL) domain comprises SEQ ID NO: 114,
(vi) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 118 and the variable light (VL) domain comprises SEQ ID NO: 121,
(vii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 144 and the variable light (VL) domain comprises SEQ ID NO: 148.

### Claim 19 (depends on 12, 13, 14, 15, 16, 17, 18)

An antibody that binds to the same epitope on OCL1 LOS as an antibody according to any one of claims 12 to 18.

### Claim 20 (depends on 12, 13, 14, 15, 16, 17, 18)

An antibody capable of competing for binding to OCL1 LOS with an antibody according to any one of claims 12 to 18.

### Claim 21 (depends on 1, 2)

An antibody according to claim 1 or claim 2, that specifically binds KL49 at the surface of Acinetobacter baumannii bacteria.

### Claim 22 (depends on 1, 2)

An antibody according to claim 1 or claim 2, that specifically binds KL49 on outer membrane vesicles (OMVs) of Acinetobacter baumannii bacteria.

### Claim 23 (depends on 21, 22)

An antibody according to claim 21 or claim 22, wherein the antibody comprises a variable heavy (VH) domain sequence comprising complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, and a variable light (VL) domain sequence comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, and wherein the HCDR3 is selected from the group consisting of SEQ ID NO: 168, SEQ ID NO: 5, SEQ ID NO: 14, SEQ ID NO: 41, SEQ ID NO: 45, SEQ ID NO: 50, SEQ ID NO: 55, SEQ ID NO: 62, SEQ ID NO: 67, SEQ ID NO: 72, SEQ ID NO: 77, SEQ ID NO: 83, SEQ ID NO: 98, SEQ ID NO: 126, SEQ ID NO: 132, SEQ ID NO: 139, SEQ ID NO: 156, and SEQ ID NO: 163.

### Claim 24 (depends on 21, 22)

An antibody according to claim 21 or claim 22, wherein the antibody comprises a variable heavy (VH) domain sequence comprising complementarity determining regions (CDRs) HCDR1, HCDR2, and HCDR3, and a variable light (VL) domain sequence comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, and wherein:
(i) HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 168, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 10,
(ii) HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 4, HCDR3 consists of SEQ ID NO: 5, LCDR1 consists of SEQ ID NO: 8, LCDR2 consists of SEQ ID NO: 9, and LCDR3 consists of SEQ ID NO: 10,
(iii) HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 14, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 19,
(iv) HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 41, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 19,
(v) HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 45, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 10,
(vi) HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 50, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 19,
(vii) HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 55, LCDR1 consists of SEQ ID NO: 58, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 59,
(viii) HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 62, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 59,
(ix) HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 67, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 59,
(x) HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 72, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 59,
(xi) HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 77, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 80,
(xii) HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 83, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 86,
(xiii) HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 97, HCDR3 consists of SEQ ID NO: 98, LCDR1 consists of SEQ ID NO: 101, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 59,
(xiv) HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 126, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 129,
(xv) HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 132, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 135,
(xvi) HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 138, HCDR3 consists of SEQ ID NO: 139, LCDR1 consists of SEQ ID NO: 142, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 86,
(xvii) HCDR1 consists of SEQ ID NO: 154, HCDR2 consists of SEQ ID NO: 155, HCDR3 consists of SEQ ID NO: 156, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 159, or
(xviii) HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 162, HCDR3 consists of SEQ ID NO: 163, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 135.

### Claim 25 (depends on 21, 22)

An antibody according to claim 21 or claim 22, wherein the antibody comprises a variable heavy (VH) domain sequence and a variable light (VL) domain sequence and wherein:
(i) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 167 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 170,
(ii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 2 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 7,
(iii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 12 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 16,
(iv) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 40 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 16,
(v) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 44 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 47,
(vi) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 49 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 52,
(vii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 54 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 57,
(viii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 61 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 64,
(ix) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 66 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 69,
(x) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 71 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 74,
(xi) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 76 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 79,
(xii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 82 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 85,
(xiii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 96 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 100,
(xiv) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 125 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 128,
(xv) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 131 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 134,
(xvi) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 137 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 141,
(xvii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 153 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 158, or
(xviii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 161 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 165,
optionally with 1, 2, 3, 4 or 5 amino acid alterations outside the complementarity determining regions (CDRs) in the variable heavy (VH) domain sequence and optionally with 1, 2, 3, 4 or 5 amino acid alterations outside the complementarity determining regions (CDRs) in the variable light (VL) domain sequence.

### Claim 26 (depends on 21, 22)

An antibody according to claim 21 or claim 22, wherein the antibody comprises a variable heavy (VH) domain sequence and a variable light (VL) domain sequence and wherein:
(i) the variable heavy (VH) comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 167 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 170,
provided that HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 168, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 10,
(ii) the variable heavy (VH) comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 2 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 7,
provided that HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 4, HCDR3 consists of SEQ ID NO: 5, LCDR1 consists of SEQ ID NO: 8, LCDR2 consists of SEQ ID NO: 9, and LCDR3 consists of SEQ ID NO: 10,
(iii) the variable heavy (VH) comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 12 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 16,
provided that HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 14, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 19,
(iv) the variable heavy (VH) comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 40 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 16,
provided that HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 41, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 19,
(v) the variable heavy (VH) comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 44 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 47,
provided that HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 45, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 10,
(vi) the variable heavy (VH) comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 49 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 52,
provided that HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 50, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 19,
(vii) the variable heavy (VH) comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 54 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 57,
provided that HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 55, LCDR1 consists of SEQ ID NO: 58, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 59,
(viii) the variable heavy (VH) comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 61 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99%/identity to SEQ ID NO: 64,
provided that HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 62, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 59,
(ix) the variable heavy (VH) comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 66 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 69,
provided that HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 67, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 59,
(x) the variable heavy (VH) comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 71 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 74,
provided that HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 72, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 59,
(xi) the variable heavy (VH) comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 76 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 79,
provided that HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 77, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 80,
(xii) the variable heavy (VH) comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 82 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 85,
provided that HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 83, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 86,
(xiii) the variable heavy (VH) comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 96 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99%/identity to SEQ ID NO: 100,
provided that HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 97, HCDR3 consists of SEQ ID NO: 98, LCDR1 consists of SEQ ID NO: 101, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 59,
(xiv) the variable heavy (VH) comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 125 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 128,
provided that HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 126, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 129,
(xv) the variable heavy (VH) comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 131 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 134,
provided that HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 132, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 135,
(xvi) the variable heavy (VH) comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 137 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 141,
provided that HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 138, HCDR3 consists of SEQ ID NO: 139, LCDR1 consists of SEQ ID NO: 142, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 86,
(xvii) the variable heavy (VH) comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 153 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 158,
provided that HCDR1 has SEQ ID NO: 154, HCDR2 has SEQ ID NO: 155, HCDR3 has SEQ ID NO: 156, LCDR1 has SEQ ID NO: 17, LCDR2 has SEQ ID NO: 18, and LCDR3 has SEQ ID NO: 159, or
(xviii) the variable heavy (VH) comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO: 161 and
the variable light (VL) domain comprises, preferably consists of a sequence having at least 90%, at least 95%, at least 98%, or at least 99%/identity to SEQ ID NO: 165,
provided that HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 162, HCDR3 consists of SEQ ID NO: 163, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 135.

### Claim 27 (depends on 21, 22)

An antibody according to claim 21 or claim 22, wherein the antibody comprises a variable heavy (VH) domain sequence and a variable light (VL) domain sequence and wherein:
(i) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 167 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 170,
(ii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 2 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 7,
(iii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 12 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 16,
(iv) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 40 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 16,
(v) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 44 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 47,
(vi) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 49 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 52,
(vii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 54 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 57,
(viii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 61 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 64,
(ix) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 66 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 69,
(x) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 71 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 74,
(xi) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 76 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 79,
(xii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 82 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 85,
(xiii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 96 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 100,
(xiv) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 125 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 128,
(xv) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 131 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 134,
(xvi) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 137 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 141,
(xvii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 153 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 158, or
(xviii) the variable heavy (VH) domain comprises, preferably consists of SEQ ID NO: 161 and the variable light (VL) domain comprises, preferably consists of SEQ ID NO: 165.

### Claim 28 (depends on 21, 22, 23, 24, 25, 26, 27)

An antibody that binds to the same epitope on KL49 as an antibody according to any one of claims 21 to 27.

### Claim 29 (depends on 21, 22, 23, 24, 25, 26, 27)

An antibody capable of competing for binding to KL49 with any an antibody according to any one of claims 21 to 27.

### Claim 30

An antibody according to any one of the preceding claims, wherein the antibody shows complement-dependant cytotoxic activity (CDC) activity.

### Claim 31

An antibody according to any one of the preceding claims, wherein the antibody is a human IgG1 or human IgG4.

### Claim 32 (depends on 31)

An antibody according to claim 31, wherein the antibody is a human IgG1, optionally wherein the antibody comprises a constant region sequence of SEQ ID NO: 418.

### Claim 33 (depends on 31)

An antibody according to claim 31, wherein the antibody is a human IgG4, optionally wherein the antibody comprises a constant region sequence of SEQ ID NO: 436.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

An antibody according to any one of claims 1 to 30, wherein the antibody is a human IgA1 (e.g., comprising a constant region sequence SEQ ID NO: 484) or human IgA2 (e.g., comprising a constant region sequence SEQ ID NO: 485).

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

An antibody according to any one of claims 1 to 34, wherein the antibody comprises kappa (κ) light chain constant regions, preferably constant domain sequence SEQ ID NO: 448.

### Claim 36

A nucleic acid sequence comprising a sequence that encodes a VH domain and/or an VL domain of an antibody according to any preceding claim.

### Claim 37

A nucleic acid sequence comprising a sequence that encodes the heavy chain and/or the light chain of an antibody according to any preceding claim.

### Claim 38 (depends on 36, 37)

A vector comprising a nucleic acid according to claim 36 or claim 37, optionally wherein the vector is a CHO vector.

### Claim 39 (depends on 36, 37, 38)

A host cell comprising a nucleic acid according to claim 36 or claim 37, or a vector according to claim 38.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

A pharmaceutical composition comprising (i) an isolated nucleic acid encoding an antibody according to any one of claims 1 to 35, or (ii) a nucleic acid according to claim 36 or claim 37, and a pharmaceutically acceptable excipient.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

A pharmaceutical composition comprising an antibody according to any one of claims 1 to 35, and a pharmaceutically acceptable excipient.

### Claim 42 (depends on 40, 41)

A pharmaceutical composition according to claim 40 or 41, wherein the pharmaceutical composition is formulated for intravenous, intramuscular, or subcutaneous administration.

### Claim 43 (depends on 40, 41, 42)

A pharmaceutical composition according to any one of claims 40 to 42, wherein the pharmaceutical composition further comprises at least one further therapeutic agent.

### Claim 44 (depends on 43)

A pharmaceutical composition according to claim 43, wherein the further therapeutic agent is at least one, preferably one or two, further antibodies.

### Claim 45 (depends on 43)

A pharmaceutical composition according to claim 43, wherein the further therapeutic agent is carbapenem.

### Claim 46 (depends on 43)

A pharmaceutical composition according to claim 43, wherein the further therapeutic agent is colistin.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

A kit comprising an antibody according to any one of claim 1 to 35.

### Claim 48 (depends on 40, 41, 42, 43, 44, 45, 46)

A kit comprising a pharmaceutical composition according to any one of claims 40 to 46.

### Claim 49 (depends on 48)

A kit according to claim 48, wherein the kit further comprises a label or instructions for use to prevent and/or treat a bacterial infection caused by Acinetobacter baumannii in a human; optionally wherein the label or instructions comprise a marketing authorisation number (e.g., an FDA or EMA authorisation number); optionally wherein the kit comprises an IV or injection device that comprises the antibody.

### Claim 50 (depends on 47, 49)

A kit according to claim 47 or claim 49, wherein the antibody is contained in a sealed container.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 40, 41, 42, 43, 44, 45, 46)

An antibody according to any one of claims 1 to 35, or a pharmaceutical composition according to any one of claims 40 to 46, or a nucleic acid according to claim 36 or claim 37, for use as a medicament.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 40, 41, 42, 43, 44, 45, 46)

An antibody according to any one of claims 1 to 35, or a pharmaceutical composition according to any one of claims 40 to 46, or a nucleic acid according to claim 36 or claim 37, for use in a method of treating a bacterial infection caused by Acinetobacter baumannii, said method comprising administering the antibody, composition, or nucleic acid to a patient.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 40, 41, 42, 43, 44, 45, 46)

An antibody according to any one of claims 1 to 35, or a pharmaceutical composition according to any one of claims 40 to 46, or a nucleic acid according to claim 36 or claim 37, for use in a method of preventing a bacterial infection caused by Acinetobacter baumannii, said method comprising administering the antibody, composition, or nucleic acid to a patient.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 40, 41, 42, 43, 44, 45, 46, 52, 53)

An antibody according to any one of claims 1 to 35, or a pharmaceutical composition according to any one of claims 40 to 46, or a nucleic acid according to claim 36 or claim 37, for use according to claim 52 or claim 53, wherein the presence or absence of Oxa-23 has been determined in a sample from the patient prior to administering the antibody, composition, or nucleic acid to the patient.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 40, 41, 42, 43, 44, 45, 46, 52, 53, 54)

An antibody according to any one of claims 1 to 35, or a pharmaceutical composition according to any one of claims 40 to 46, or a nucleic acid according to claim 36 or claim 37, for use according to claim 52, claim 53 or claim 54, wherein the presence or absence of OCL1 LOS has been determined in a sample from the patient prior to administering the antibody, composition, or nucleic acid to the patient.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 40, 41, 42, 43, 44, 45, 46, 52, 53, 54, 55)

An antibody according to any one of claims 1 to 35, or a pharmaceutical composition according to any one of claims 40 to 46, or a nucleic acid according to claim 36 or claim 37, for use according to any one of claims 52 to 55, wherein the presence or absence of KL49 has been determined in a sample from the patient prior to administering the antibody, composition, or nucleic acid to the patient.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 40, 41, 42, 43, 44, 45, 46)

Use of an antibody according to any one of claims 1 to 35, or a pharmaceutical composition according to any one of claims 40 to 46, or a nucleic acid according to claim 36 or claim 37, in the manufacture of a medicament for use in a method of treating a bacterial infection caused by Acinetobacter baumannii in a patient.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 40, 41, 42, 43, 44, 45, 46)

Use of an antibody according to any one of claims 1 to 35, or a pharmaceutical composition according to any one of claims 40 to 46, or a nucleic acid according to claim 36 or claim 37, in the manufacture of a medicament for use in a method of preventing a bacterial infection caused by Acinetobacter baumannii in a patient.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 40, 41, 42, 43, 44, 45, 46)

A method of treating a bacterial infection caused by Acinetobacter baumannii in a patient comprising administering to said patient a therapeutically effective amount of an antibody according to any one of claims 1 to 35, or a pharmaceutical composition according to any one of claims 40 to 46, or a nucleic acid according to claim 36 or claim 37.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 40, 41, 42, 43, 44, 45, 46)

A method of preventing a bacterial infection caused by Acinetobacter baumannii in a patient comprising administering to said patient a therapeutically effective amount of an antibody according to any one of claims 1 to 35, or a pharmaceutical composition according to any one of claims 40 to 46, or a nucleic acid according to claim 36 or claim 37.

### Claim 61 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60)

An antibody, composition, or nucleic acid for use according to any one of claims 52 to 56, use according to claim 57 or claim 58, or a method according to claim 59 or claim 60, wherein the bacterial infection caused by Acinetobacter baumannii is a nosocomial bacterial infection caused by Acinetobacter baumannii.

### Claim 62 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60)

An antibody, composition, or nucleic acid for use according to any one of claims 52 to 56, use according to claim 57 or claim 58, or a method according to claim 59 or claim 60, wherein the patient has a lower respiratory tract infection, for example pneumonia.

### Claim 63 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60)

An antibody, composition, or nucleic acid for use according to any one of claims 52 to 56, use according to claim 57 or claim 58, or a method according to claim 59 or claim 60, wherein the patient has sepsis.

### Claim 64 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60)

An antibody, composition, or nucleic acid for use according to any one of claims 52 to 56, use according to claim 57 or claim 58, or a method according to claim 59 or claim 60, wherein the patient has bacteremia.

### Claim 65 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60)

An antibody, composition, or nucleic acid for use according to any one of claims 52 to 56, use according to claim 57 or claim 58, or a method according to claim 59 or claim 60, wherein the method further comprises administering at least one further therapeutic agent.

### Claim 66 (depends on 65)

An antibody, composition, or nucleic acid for use according to claim 65, use according to claim 65, or a method according to claim 65, wherein the administration of the further therapeutic agent is simultaneous, separate or sequential.

### Claim 67 (depends on 65, 66)

An antibody, composition, or nucleic acid for use according to claim 65 or claim 66, use according to claim 65 or claim 66, or a method according to claim 65 or claim 66, wherein the further therapeutic agent is at least one, preferably one or two, further antibodies.

### Claim 68 (depends on 65, 66, 67)

An antibody, composition, or nucleic acid for use according to any one of claims 65 to 67, use according to any one of claims 65 to 67, or a method according to any one of claims 65 to 67, wherein the at least one further therapeutic agent is carbapenem.

### Claim 69 (depends on 65, 66, 67)

An antibody, composition, or nucleic acid for use according to any one of claims 65 to 67, use according to any one of claims 65 to 67, or a method according to any one of claims 65 to 67, wherein the at least one further therapeutic agent is colistin.

### Claim 70 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

Use of an antibody according to any one of claims 1 to 35, for determining the presence or absence of Acinetobacter baumannii in a sample.

### Claim 71

A method of determining the presence or absence of Acinetobacter baumannii in a sample comprising contacting the sample with an antibody according to any one of 1 to 35; and testing for binding between the antibody and Acinetobacter baumannii in the sample; wherein detection of binding indicates the presence of Acinetobacter baumannii in the sample and wherein absence of binding indicates the absence of Acinetobacter baumannii in the sample.

### Claim 72 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

Use of an antibody according to any one of claims 1 to 11 for determining the presence or absence of Oxa-23 in a sample, optionally wherein determining the presence or absence of Oxa-23 in a sample is used for determining a treatment protocol in a patient.

### Claim 73 (depends on 1, 2)

Use of an antibody according to any one of claims 1, 2, or 12 to 20 for determining the presence or absence of OCL1 LOS in a sample, optionally wherein determining the presence or absence of OCL1 LOS in a sample is used for determining a treatment protocol in a patient.

### Claim 74 (depends on 1, 2)

Use of an antibody according to any one of claims 1, 2, or 21 to 29 for determining the presence or absence of KL49 in a sample, optionally wherein determining the presence or absence of KL49 in a sample is used for determining a treatment protocol in a patient.

### Claim 75 (depends on 72, 73, 74)

Use according to any one of claims 72 to 74, wherein the antibody is conjugated to a detectable label.

### Claim 76 (depends on 72, 73, 74, 75)

Use according to any one of claims 72 to 75, wherein the sample has been obtained from a human who has been or is suspected of having been infected with Acinetobacter baumannii.

### Claim 77 (depends on 76)

Use according to claim 76, wherein the sample has been obtained from a human who has been or is suspected of having been infected with Acinetobacter baumannii who exhibits one or more symptoms of a bacterial infection.

### Claim 78 (depends on 72, 73, 74, 75, 76, 77)

Use according to any one of claims 72 to 77, wherein the sample is a serum, plasma, or whole blood sample, an oral or nasal swab, urine, faeces, or cerebrospinal fluid (CFS), or wherein the sample is from any suspected Acinetobacter baumannii infected organ or tissue.

### Claim 79 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

A diagnostic kit comprising an antibody according to any one of claims 1 to 35, and optionally one or more buffering solutions.

### Claim 80 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 79)

A diagnostic kit according to claim 79, wherein the kit comprises a first reagent comprising the antibody according to any one of claims 1 to 35, and a second reagent comprising a detector molecule that binds to the first reagent.

### Claim 81 (depends on 80)

A diagnostic kit according to claim 80, wherein the detector molecule is an antibody that comprises or is conjugated to a detectable label.
